IP Library Granted Patent US 7,691,099
Granted Patent B2
US 7,691,099 · App. 11/825,816 · Granted Apr 6, 2010

Deuterated ocular solutions for LTK and other surgical eye procedures

Assignee: NTK Enterprises, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,691,099
App. No.
11/825,816
Granted
Apr 6, 2010
Kind
B2
Abstract

A deuterated ocular solution is applied to an eye. The deuterated ocular solution includes deuterated water and one or more ocular drugs (such as proparacaine). A protective corneal device is applied to a cornea of the eye. The device includes a window configured to contact at least a portion of the cornea. At least part of the cornea is irradiated using light energy that passes through the window during a cornea reshaping procedure, where the window is substantially transparent to the light energy. The window of the protective corneal device and the deuterated ocular solution may prevent clinically significant damage to a corneal epithelium of the cornea during the cornea reshaping procedure, such as by preventing a temperature of the corneal epithelium from exceeding approximately 70° C. during the cornea reshaping procedure. This may help to avoid a wound healing response in the eye and an associated regression of refractive correction.

Claims (17)

1. A method comprising:

applying a deuterated ocular solution to an eye, the eye comprising a cornea, the deuterated ocular solution comprising deuterated water and one or more ocular drugs, the one or more ocular drugs causing swelling of a corneal epithelium in the cornea;

applying a device to the cornea of the eye, the device comprising a window configured to contact at least a portion of the cornea; and

irradiating at least part of the cornea to modify a stroma in the cornea using light energy that passes through the window and through the corneal epithelium during a cornea reshaping procedure, the window substantially transparent to the light energy.

2. The method of claim 1 , wherein the one or more ocular drugs comprise proparacaine.

3. The method of claim 1 , further comprising:

preventing, using the window and the deuterated ocular solution, clinically significant damage to the corneal epithelium of the cornea during the cornea reshaping procedure.

4. The method of claim 3 , wherein preventing clinically significant damage to the corneal epithelium comprises preventing a temperature of the corneal epithelium from exceeding approximately 70° C during the cornea reshaping procedure.

5. The method of claim 1 , further comprising:

maintaining at least a portion of the cornea at a desired initial temperature prior to irradiation of the cornea.

6. The method of claim 1 , further comprising:

causing at least a portion of the cornea to have a desired shape using the window prior to irradiation of the cornea.

7. The method of claim 6 , wherein the desired shape is substantially equal to at least one desired final radius of curvature of the cornea.

8. The method of claim 1 , further comprising:

coupling the device to a fiber optic holder, the device comprising a first magnet configured to attract a second magnet in the fiber optic holder.

9. The method of claim 1 , further comprising: generating the light energy using a continuous wave laser.

10. The method of claim 1 , wherein a mixture of deuterated water, monodeuterated water, and protonated water forms in the coeal epithelium, the mixture having a lower absorption coefficient compared to protonated water such that an effect of the swelling on a dosimetry of the light energy is reduced.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2007
From: BERRY, MICHAEL J.
To: NTK ENTERPRISES, INC.
Reel/Frame 019592/0016 →
Continuity (2)
Provisional Application 6083029200 · Jul 12, 2006
Related Publication 20080027418A1 · Jan 31, 2008